The COVID-19 pandemic has thrown multiple operational and financial challenges for organisations and businesses across the world.

GlobalData has conducted a survey to assess the primary concerns for pharmaceutical businesses related to the COVID-19 outbreak in Q1 and Q3 2020.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Primary business concerns related to Covid-19 outbreak

Primary concerns for pharmaceutical businesses related to the COVID-19 outbreak

Analysis of the survey results shows that employee safety remained the primary concern between Q1 and Q3 and the concern has only increased.

A majority 21% of the respondents opined that employee safety was their primary business concern in Q1, which increased to 23% in Q3.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Impact on supply chains was the next biggest concern as opined by 20% in Q1 and 19% in Q3.

While 16% of the respondents opined that clinical trial disruption was the primary concern in Q1, the percentage declined to 15% in Q3. Concerns over CRO disruptions increased in Q3 to 12%, from 10% in Q1.

Money raising was considered as the primary concern by 10% of the respondents in Q1, but declined to 9% in Q3. Respondents considering business development as a primary concern increased from 8% in Q1 to 9% in Q3.

Another 7% voted that medical meeting closures were the primary concern in Q1, which declined to 4% in Q3, while 6% voted for sales representatives’ access to physicians as the primary concern in Q1, which declined to 5% in Q3 and 2% listed other reasons as their primary concerns in Q1, which increased to 3% in Q3.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey fielded between 07 July and 30 July 2020.